• linkedin
  • Increase Font
  • Sharebar

    A Triple Hitter in One Blast: COPD Lessons from TRILOGY


    Patients with severe COPD are likely to suffer frequent disease exacerbations and a reduced quality of life. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend dual agent therapy consisting of an inhaled corticosteroid (ICS) plus either a long acting beta agonist (LABA) or a long acting anticholinergic medication (LAMA) for patients with severe disease. The GOLD guidelines also offer alternative recommendations for patients who do not respond adequately to dual inhaler therapy—including adding both LABA and LAMA medications with an ICS. But this strategy has not been well studied and the need for additional inhalers could decrease patient compliance and ultimately not lead to improved care. 

    The “Single Inhaler Triple Therapy Versus Inhaled Corticosteroid Plus Long-acting β-agonist Therapy for Chronic Obstructive Pulmonary Disease (TRILOGY)” trial investigated the use of triple drug therapy in a novel single inhaler in patients with severe COPD. TRILOGY was a double-blind parallel group study that randomized 1368 subjects across 159 study sites in 14 countries. Eligible patients had FEV1 of less than 50%, one or more COPD exacerbations in the previous 12 months, a COPD Assessment Test score of 10 or more, along with a Baseline Dyspnea Index score of 10 or less.

    Patients in the control group received a combination inhaler containing beclomethasone dipropionate (100 µg) and formoterol fumerate (6 µg) (BDP/FF). The study group received a newly designed triple therapy inhaler containing beclomethasone dipropionate (100 µg), formoterol fumerate (6 µg) and glycopyrronium bromide (12.5 µg) (BDP/FF/GB). Each group also received a salbutamol inhaler as a rescue medication. The between group comparison included three primary endpoints assessed at 26 weeks:

    . Change from baseline pre-dose morning FEV1

    . Change from baseline in 2 hour post-dose FEV1

    . Transitional Dyspnea Index (TDI) focal score

    Secondary endpoints included time to first exacerbation, exacerbation frequency, rescue inhaler use, TDI focal score at all clinic visits, and St George’s Respiratory Questionnaire (SGRQ) total score.

    The primary findings included a statistically significant improvement in pre-dose FEV1 in the BDP/FF/GB group of 0.081L (p<0.001) and 2 hour post dose FEV1 by 0.117L (p<0.001). The difference in the TDI focal score at the end of 26 weeks was not significant between the two groups—but was at various points throughout the study (weeks 4 and 12). Other differences between groups included a 23% decrease in COPD exacerbations in the treatment group, as well as a decrease in use of rescue treatment.

    Compliance was very good—at 95.6% of doses in the triple therapy group and 95% in the BDP/FF study population.

    Adverse events were similar between the groups. Most were classified as mild or moderate in severity. Only one serious adverse event occurred: atrial fibrillation in a BDP/FF/GB recipient resolved and did not lead to study drug discontinuation.

    Michael Smith, PharmD, BCPS, CACP
    Michael L. Smith, PharmD, BCPS, CACP, is the pharmacy clinical manager, East Region, Hartford Healthcare, Hartford, Conn., and adjunct ...


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • Anonymous
      I am 54 years old and I was told I had COPD 7 years ago. I immediately quit smoking, but as the years pass by my condition got significantly worse, and I started having serious attacks. I used to be able to exercise, but it became so hard because I`m constantly out of breath. My pulmonologist started me on oral steroids to help control symptoms and minimize further damage but my symptoms never stopped getting worse. In January this year, my pulmonologist and I decided to go with natural treatment and was introduced to NewLife Herbal Clinic natural organic COPD Herbal formula, i had a total decline of symptoms with this COPD Herbal formula treatment. The infections, shortness of breath, fatigue, dry cough and other symptoms has subsided. Visit NewLife Herbal Clinic official website ww w. newlifeherbalclinic. com or email [email protected] newlifeherbalclinic. com. I have had great improvement with my over all respiration with this product and i breath very much easier, i can never be thankful enough to nature
    • [email protected]
      Hello..,My Uncle and his Wife was diagnosed with silicosis disease and COPD disease December 2013, they were given several medications to ease their condition as My Uncle was told there was no cure for both diseases. their symptoms were mainly shortness of breath, cough and weight loss that continued for over 3 years progressively getting worse.i saw so many post online about perfect health herbal medicine,people saying they cure different kinds of deadly diseases like,Parkinson,COPD,IPF,Chronic pancreatitis,Hepatitis b,ALS,Herpes,and so many more, I decided to give the perfect health herbal medicine a try.so contacted them via their email perfecthealthherbalmedicine(AT)gmail(DOT)com,website www(DOT)perfecthealthherbal(DOT)weebly(DOT)com.so we purchased the herbal medicine,which was shipped to us,My uncle and his wife herbal medicine treatment took 35days in total to be cured. I would say a majority of my uncle and his wife symptoms dissapeared 20days after treatment began.they went for a follow up spirometry test and my doctor couldn’t believe they was the same husband and wife he saw the last time and My doctor confirmed their lungs were functioning better now 100%, Its unbelievable! I thank perfect health herbal medicine from the bottom of my heart for giving my uncle and his wife life back.